Heron Therapeutics launches patent suit against Mylan over potential generic for chemo-related nausea
Heron Therapeutics filed suit in Delaware federal court on Friday to block Mylan Pharmaceuticals’ generic version of a drug used for chemotherapy-associated nausea.
Heron’s Cinvanti was first approved in 2017 as an IV formulation to prevent nausea and vomiting in patients taking chemo, rivaling Merck’s Emend. Though Cinvanti contains the same active ingredient, aprepitant, Heron marketed the drug as a new option for patients without an additive called polysorbate 80, which had been linked to anaphylaxis and injection site reactions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.